(Q35817235)

10 August 2017

1 reference

title

Neuroprotection in Parkinson's disease: an elusive goal. (English)

1 reference

10 August 2017

1 reference

William C Koller

1

1 reference

PubMed ID

15217541

10 August 2017

Maria G Cersosimo

series ordinal

2

1 reference

10 August 2017

1 July 2004

1 reference

Current Neurology and Neuroscience Reports

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

4

1 reference

10 August 2017

277-283

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-004-0052-2

10 August 2017

0 references

cites work

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

1 reference

https://api.crossref.org/works/10.1007%2FS11910-004-0052-2

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-004-0052-2

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-004-0052-2

Freezing of gait in PD: prospective assessment in the DATATOP cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-004-0052-2

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-004-0052-2

A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-004-0052-2

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

12 December 2020

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

12 December 2020

Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection.

1 reference

12 December 2020

Designing neuroprotection trials in Parkinson's disease

1 reference

12 December 2020

Neurodegeneration and neuroprotection in Parkinson disease

1 reference

12 December 2020

Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease

1 reference

12 December 2020

Imaging end points for monitoring neuroprotection in Parkinson's disease.

1 reference

12 December 2020

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

1 reference

12 December 2020

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

12 December 2020

Proteasomal function is impaired in substantia nigra in Parkinson's disease

1 reference

12 December 2020

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

1 reference

12 December 2020

The effect of deprenyl and levodopa on the progression of Parkinson's disease

1 reference

12 December 2020

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

1 reference

12 December 2020

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.

1 reference

12 December 2020

Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration

1 reference

12 December 2020

1 reference

12 December 2020

Oxidative damage in neurodegenerative disease

1 reference

12 December 2020

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

12 December 2020

1 reference

12 December 2020

Parkinson disease in twins: an etiologic study

1 reference

12 December 2020

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl

1 reference

12 December 2020

Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease

1 reference

12 December 2020

Environmental risk factors in Parkinson's disease

1 reference

12 December 2020

The subthalamic nucleus and its connections. New electrophysiological and pharmacological data

1 reference

12 December 2020

Mitochondrial complex I deficiency in Parkinson's disease

1 reference

12 December 2020

Apoptosis in Parkinson's disease: signals for neuronal degradation

1 reference

12 December 2020

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

12 December 2020

Selegiline as a primary treatment of Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

1 reference

12 December 2020

Understanding cell death in Parkinson's disease.

1 reference

12 December 2020

Etiology and pathogenesis of Parkinson's disease

1 reference

12 December 2020

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

12 December 2020

Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal

1 reference

12 December 2020

The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality

1 reference

12 December 2020

1 reference

12 December 2020

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

1 reference

12 December 2020

Dopamine agonists and neuroprotection in Parkinson's disease

1 reference

12 December 2020

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

Pharmacology and neuroprotective properties of rasagiline

1 reference

12 December 2020

Bioenergetic approaches for neuroprotection in Parkinson's disease

1 reference

12 December 2020

Abnormalities of the electron transport chain in idiopathic Parkinson's disease

1 reference

12 December 2020

Therapeutic potential of nerve growth factors in Parkinson's disease

1 reference

12 December 2020

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

1 reference

12 December 2020

10.1007/S11910-004-0052-2

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15217541